[go: up one dir, main page]

WO2015095337A3 - PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT - Google Patents

PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT Download PDF

Info

Publication number
WO2015095337A3
WO2015095337A3 PCT/US2014/070876 US2014070876W WO2015095337A3 WO 2015095337 A3 WO2015095337 A3 WO 2015095337A3 US 2014070876 W US2014070876 W US 2014070876W WO 2015095337 A3 WO2015095337 A3 WO 2015095337A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
treating cognitive
cognitive impairment
pyrimidinecarboxamide derivatives
pyrimidinecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/070876
Other languages
French (fr)
Other versions
WO2015095337A2 (en
Inventor
Hyung Jin Ahn
J. Fraser Glickman
Sidney Strickland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of WO2015095337A2 publication Critical patent/WO2015095337A2/en
Publication of WO2015095337A3 publication Critical patent/WO2015095337A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds of formula I and II: Formula (I) or Formula (II) inhibit the interaction between fibrinogen and amyloid-β and are useful for treating cognitive disorders such as memory impairment and Alzheimer's disease.
PCT/US2014/070876 2013-12-18 2014-12-17 PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT Ceased WO2015095337A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917648P 2013-12-18 2013-12-18
US61/917,648 2013-12-18

Publications (2)

Publication Number Publication Date
WO2015095337A2 WO2015095337A2 (en) 2015-06-25
WO2015095337A3 true WO2015095337A3 (en) 2015-11-12

Family

ID=53403877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/070876 Ceased WO2015095337A2 (en) 2013-12-18 2014-12-17 PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT

Country Status (1)

Country Link
WO (1) WO2015095337A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718581A (en) 2015-10-19 2017-06-01 英塞特公司 Heterocyclic compounds as immunomodulators
LT3377488T (en) 2015-11-19 2023-01-10 Incyte Corporation HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
MA44860A (en) 2016-05-06 2019-03-13 Incyte Holdings Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JP7303108B2 (en) 2016-12-22 2023-07-04 インサイト・コーポレイション Bicyclic heteroaromatic compounds as immunomodulators
CN116115764A (en) 2016-12-22 2023-05-16 因赛特公司 Tetrahydroimidazo[4,5-C]pyridine derivatives as PD-L1 internalization inducers
ES3030010T3 (en) 2018-03-30 2025-06-26 Incyte Corp Heterocyclic compounds as immunomodulators
BR112020022936A2 (en) 2018-05-11 2021-02-02 Incyte Corporation tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2023500395A (en) 2019-11-11 2023-01-05 インサイト・コーポレイション Salts and Crystal Forms of PD-1/PD-L1 Inhibitors
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
TW202233616A (en) 2020-11-06 2022-09-01 美商英塞特公司 Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082902A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20100305091A1 (en) * 2007-07-20 2010-12-02 Stanton Matthew G PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082902A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20100305091A1 (en) * 2007-07-20 2010-12-02 Stanton Matthew G PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 20 July 2009 (2009-07-20), Database accession no. 42877636 *
DATABASE PubChem 20 July 2009 (2009-07-20), Database accession no. AGN-PC-06CYCR *
DATABASE PubChem 22 June 2010 (2010-06-22), Database accession no. 07 MG 50 *
ZOU ET AL.: "Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization", CELL RESEARCH, vol. 17, 2007, pages 389 - 401, XP055237720, ISSN: 1001-0602 *

Also Published As

Publication number Publication date
WO2015095337A2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2015095337A3 (en) PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
GEP20166554B (en) Nitrogenated heterocyclic compound
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX388140B (en) SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
HK1207069A1 (en) Heterocyclic compounds and uses thereof
BR112014028395A2 (en) substituted 3,4-dihydro-2h-pyrido [1,2-a] pyrazine-1,6-dione derivatives useful for the treatment of (inter alia) alzheimer's disease
MX2015008957A (en) Fluoro-[1,3]oxazines as bace1 inhibitors.
HK1203927A1 (en) Heterocyclic compounds and uses as anticancer agents
HK1206726A1 (en) Imidazotriazinone compounds
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
HK1247203A1 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
EP3307738A4 (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
NZ704863A (en) Bicyclic pyridinones useful as gamma secretase modulators
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
WO2015110491A3 (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
WO2015042414A8 (en) Multicyclic compounds and methods of using same
IN2014DN09826A (en)
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2015002755A3 (en) Compounds for the treatment of malaria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14871283

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14871283

Country of ref document: EP

Kind code of ref document: A2